Vanda urges FDA to drop proposal for extending drug review timelines; shares down

ReutersApr 9, 2026 3:19 PM

Shares of drugmaker Vanda Pharmaceuticals VNDA.O fall 1.4% to $7.19 in early trading

Co says it asked the FDA to withdraw a proposal that would lengthen reviews of new drug applications

Says the plan would scrap a law requiring drug reviews within 180 days and instead allow reviews to stretch 10–12 months

Adds the change could delay patient access to medicines and raise uncertainty for smaller drugmakers

The proposal would replace a formal appeal process for rejected drugs with a less rigorous internal review - VNDA

Including session's move, stock down ~19% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Adobe Stock Price Hits 2019 Low: Is Generative AI a Real Threat, or Is It Time to Buy the Dip?

TradingKey - Adobe Inc. (ADBE) reached a multi-year low of $224.13 on April 10, the first time since 2019. This decline is part of a more significant trend resetting for the software sector, driven by worries about the effect that generative AI will have on creative tools, as well as uncertainty reg

Nvidia Releases Open-Source Quantum AI Model Ising, Quantum Computing Sector Rises Collectively, IonQ Gains Over 20%

TradingKey - On April 14, 2026, local time, NVIDIA (NVDA) officially released NVIDIA Ising, an open-source quantum AI model licensed under Apache-2.0. The model focuses on two core engineering challenges: quantum processor calibration and quantum error correction.

2026 Global AI Industry Deep Observation: Technological Leadership Is Not the End Game, Analyzing the Commercialization Watershed of Anthropic and OpenAI

Deep Analysis of the 2026 AI Industry Watershed: How Anthropic achieved $30 billion in revenue through a precise B2B strategy and surpassed OpenAI in monetization efficiency. This article compares the valuation logic of Claude versus ChatGPT, analyzes the rise of disruptors such as Cursor, Perplexity, and Meta, and reveals the endgame truth of the AI industry's transition from a technological arms race to a battle for ecosystem positioning.

Anthropic IPO vs OpenAI IPO: Can an $800 Billion Valuation Help Anthropic Claim the First Large Model Stock?

TradingKey – An $800 billion valuation for Anthropic: this is the most staggering figure in the global AI investment circle as of April 2026. According to Business Insider, several venture capital firms have proactively extended investment offers to Claude developer Anthropic, with valuations reaching up to $800 billion—double the $380 billion valuation from its Series G round just two months prior. Notably, Anthropic has yet to accept any new funding, despite Silicon Valley capital vying for a stake. With the company set to launch its IPO as early as October 2026, the battle for the title of "the first public LLM stock" between the Anthropic IPO and the OpenAI IPO has officially begun.

TSMC Earnings Preview: Q1 Revenue Hits 1T NTD with Projected 50% Profit Surge; Wall Street Warns of Margin Peak

TradingKey - Last Friday (April 10), TSMC reported record quarterly revenue—consolidated revenue for Q1 FY2026 reached NT$1.134 trillion (approximately US$35.6 billion), up approximately 35% year-on-year. This marks the first time single-quarter revenue has surpassed the NT$1 trillion threshold.

Featured Tools